| 1 |
Yang W, Ge J, Yuan M, Li J, Pan L, Ren J, Dou G, Yang L, Zhou Y, Xie H, Wang X, Hu H. Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C. Anticancer Drugs 2023:e001428. [PMID: 36847041 DOI: 10.1097/CAD.0000000000001428] [Reference Citation Analysis]
|
| 2 |
Schein CH. Distinguishing Curable from Progressive Dementias for Defining Cancer Care Options. Cancers (Basel) 2023;15. [PMID: 36831398 DOI: 10.3390/cancers15041055] [Reference Citation Analysis]
|
| 3 |
Xu LS, Zheng SX, Mei LH, Yang KX, Wang YF, Zhou Q, Kong XT, Zheng MY, Jiang HL, Xie CY. 143D, a novel selective KRAS(G12C) inhibitor exhibits potent antitumor activity in preclinical models. Acta Pharmacol Sin 2023. [PMID: 36725884 DOI: 10.1038/s41401-023-01053-2] [Reference Citation Analysis]
|
| 4 |
Veccia A, Dipasquale M, Kinspergher S, Monteverdi S, Girlando S, Barbareschi M, Caffo O. Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy. Target Oncol 2023;18:129-38. [PMID: 36482151 DOI: 10.1007/s11523-022-00934-6] [Reference Citation Analysis]
|
| 5 |
Hilzenrat RA, Yip S, Melosky B, Ho C, Laskin J, Sun S, Choi JJ, McGuire AL. Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Curr Oncol 2022;30:145-56. [PMID: 36661661 DOI: 10.3390/curroncol30010012] [Reference Citation Analysis]
|
| 6 |
Gelb BD, Yohe ME, Wolf C, Andelfinger G. New prospectives on treatment opportunities in RASopathies. Am J Med Genet C Semin Med Genet 2022;190:541-60. [PMID: 36533679 DOI: 10.1002/ajmg.c.32024] [Reference Citation Analysis]
|
| 7 |
Mullaguri SC, Akula S, Sahoo PS, Ashireddygari VR, Mupparapu V, Silveri R, Prasad Burra VLS, Kancha RK. Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants. 3 Biotech 2022;12:343. [DOI: 10.1007/s13205-022-03407-9] [Reference Citation Analysis]
|
| 8 |
Therachiyil L, Anand A, Azmi A, Bhat A, Korashy HM, Uddin S. Role of RAS signaling in ovarian cancer. F1000Res 2022;11:1253. [PMID: 36451660 DOI: 10.12688/f1000research.126337.1] [Reference Citation Analysis]
|
| 9 |
Burska AN, Ilyassova B, Dildabek A, Khamijan M, Begimbetova D, Molnár F, Sarbassov DD. Enhancing an Oxidative “Trojan Horse” Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside. Cells 2022;11:3454. [DOI: 10.3390/cells11213454] [Reference Citation Analysis]
|
| 10 |
Song Z, Lou L, Fan G, Liu L, Ge Y, Liu H, Chan AS, Zhang X, Xiong X. Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114907] [Reference Citation Analysis]
|
| 11 |
Issahaku AR, Mukelabai N, Agoni C, Rudrapal M, Aldosari SM, Almalki SG, Khan J. Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS(G12D) inhibitors for cancer therapy. Sci Rep 2022;12:17796. [PMID: 36273239 DOI: 10.1038/s41598-022-22668-1] [Reference Citation Analysis]
|
| 12 |
Ma Y, Nikfarjam M, He H. The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma. Cancer Lett 2022;548:215868. [PMID: 36027997 DOI: 10.1016/j.canlet.2022.215868] [Reference Citation Analysis]
|
| 13 |
Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, Zhang W, Qin JJ. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer 2022;21:159. [PMID: 35922812 DOI: 10.1186/s12943-022-01629-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 14 |
Kato S, Fujiwara Y, Hong DS. Targeting KRAS: Crossroads of Signaling and Immune Inhibition. Journal of Immunotherapy and Precision Oncology 2022;5:68-78. [DOI: 10.36401/jipo-22-5] [Reference Citation Analysis]
|
| 15 |
Tsumura T, Doi K, Marusawa H. Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. Cancers 2022;14:3674. [DOI: 10.3390/cancers14153674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Osei-Bordom DC, Serifis N, Brown ZJ, Hewitt DB, Lawal G, Sachdeva G, Cloonan DJ, Pawlik TM. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies. Surg Oncol 2022;43:101803. [PMID: 35830772 DOI: 10.1016/j.suronc.2022.101803] [Reference Citation Analysis]
|
| 17 |
Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, Janku F, Skoulidis F, Heymach JV, Kopetz S, Meric-Bernstam F, Hong DS. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol 2022;6:e2100547. [PMID: 35862868 DOI: 10.1200/PO.21.00547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Li J, Li R, Ma L, Wang P, Xu D, Huang J, Li L, Tang L, Xie Y, Leung EL, Yan P. Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives. Front Pharmacol 2022;13:875330. [DOI: 10.3389/fphar.2022.875330] [Reference Citation Analysis]
|
| 19 |
Liu S, Geng S, Shi N, Zhang L, Xue W, Li Y, Jiang K. Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation. Front Pharmacol 2022;13:878540. [PMID: 35401171 DOI: 10.3389/fphar.2022.878540] [Reference Citation Analysis]
|
| 20 |
McGuire AL, McConechy MK, Melosky BL, English JC, Choi JJ, Peng D, Yee J, Furman BLS, Aguirre Hernandez R, Feijao P, Mulder D, Hughesman C, Yip S. The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis. Curr Oncol 2022;29:2630-43. [PMID: 35448189 DOI: 10.3390/curroncol29040215] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Negri F, Bottarelli L, de'Angelis GL, Gnetti L. KRAS: A Druggable Target in Colon Cancer Patients. Int J Mol Sci 2022;23:4120. [PMID: 35456940 DOI: 10.3390/ijms23084120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 22 |
Bontoux C, Hofman V, Brest P, Ilié M, Mograbi B, Hofman P. Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner. Cancers (Basel) 2022;14:1628. [PMID: 35406400 DOI: 10.3390/cancers14071628] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 23 |
Vaclova T, Chakraborty A, Sherwood J, Ross S, Carroll D, Barrett JC, Downward J, de Bruin EC. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Sci Rep 2022;12:2699. [PMID: 35177674 DOI: 10.1038/s41598-022-06369-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 24 |
Xu J, Zhang C, Cheng C, Yang J, Li C, Liu X, Sang Y. A Tasquinomod-loaded dopamine-modified pH sensitive hydrogel is effective at inhibiting the proliferation of KRAS mutant lung cancer cells. J Appl Biomater Funct Mater 2022;20:22808000211073729. [PMID: 35088614 DOI: 10.1177/22808000211073729] [Reference Citation Analysis]
|
| 25 |
Shen M, Qi R, Ren J, Lv D, Yang H. Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer. Front Oncol 2021;11:780655. [PMID: 35070984 DOI: 10.3389/fonc.2021.780655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 26 |
Kwan AK, Piazza GA, Keeton AB, Leite CA. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-021-02225-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 27 |
Asimgil H, Ertetik U, Çevik NC, Ekizce M, Doğruöz A, Gökalp M, Arık-Sever E, Istvanffy R, Friess H, Ceyhan GO, Demir IE. Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight 2022;7:e153688. [PMID: 35014625 DOI: 10.1172/jci.insight.153688] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 28 |
He H, Dumesny C, Ang CS, Dong L, Ma Y, Zeng J, Nikfarjam M. A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine. Transl Oncol 2022;16:101329. [PMID: 34973571 DOI: 10.1016/j.tranon.2021.101329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 29 |
Forshaw TE, Tsang AW, Furdui CM. A thiol chemistry perspective on redox medicine. Redox Chemistry and Biology of Thiols 2022. [DOI: 10.1016/b978-0-323-90219-9.00006-6] [Reference Citation Analysis]
|
| 30 |
Chen L, Zhang J, Wang X, Li Y, Zhou L, Lu X, Dong G, Sheng C. Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models. Acta Pharm Sin B 2022;12:274-90. [PMID: 35127385 DOI: 10.1016/j.apsb.2021.07.009] [Reference Citation Analysis]
|
| 31 |
Hsu J, Annunziata JF, Burns E, Bernicker EH, Olsen RJ, Thomas JS. Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status. Clin Pathol 2022;15:2632010X221102054. [PMID: 35634237 DOI: 10.1177/2632010X221102054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 32 |
Poloznikov A, Nikulin S, Bolotina L, Kachmazov A, Raigorodskaya M, Kudryavtseva A, Bakhtogarimov I, Rodin S, Gaisina I, Topchiy M, Asachenko A, Novosad V, Tonevitsky A, Alekseev B. 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells. Front Pharmacol 2021;12:777114. [PMID: 34955846 DOI: 10.3389/fphar.2021.777114] [Reference Citation Analysis]
|
| 33 |
Jacobs F, Cani M, Malapelle U, Novello S, Napoli VM, Bironzo P. Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients. Cancers (Basel) 2021;13:6332. [PMID: 34944952 DOI: 10.3390/cancers13246332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Palma G, Khurshid F, Lu K, Woodward B, Husain H. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. NPJ Precis Oncol 2021;5:98. [PMID: 34845311 DOI: 10.1038/s41698-021-00237-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 35 |
Ruiz-Patiño A, Rodríguez J, Cardona AF, Ávila J, Archila P, Carranza H, Vargas C, Otero J, Arrieta O, Zatarain-Barrón L, Sotelo C, Ordoñez C, García-Robledo JE, Rojas L, Bermúdez M, Gámez T, Mayorga D, Corrales L, Martín C, Recondo G, Mas L, Samtani S, Ricaurte L, Malapelle U, Russo A, Barrón F, Santoyo N, Rolfo C, Rosell R; ONCOLGroup., CLICaP. p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. Transl Oncol 2022;15:101276. [PMID: 34823093 DOI: 10.1016/j.tranon.2021.101276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 36 |
Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 37 |
[DOI: 10.1145/3458817.3476210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 38 |
Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 2021;20:143. [PMID: 34742312 DOI: 10.1186/s12943-021-01441-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
|
| 39 |
Yu J, Mahipal A, Kim R. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. Onco Targets Ther 2021;14:5145-60. [PMID: 34720591 DOI: 10.2147/OTT.S272208] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 40 |
Nagasaka M, Potugari B, Nguyen A, Sukari A, Azmi AS, Ou SI. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat Rev 2021;101:102309. [PMID: 34715449 DOI: 10.1016/j.ctrv.2021.102309] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 41 |
Nussinov R, Zhang M, Maloney R, Tsai CJ, Yavuz BR, Tuncbag N, Jang H. Mechanism of activation and the rewired network: New drug design concepts. Med Res Rev 2021. [PMID: 34693559 DOI: 10.1002/med.21863] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 42 |
Giampieri R, Lupi A, Ziranu P, Bittoni A, Pretta A, Pecci F, Persano M, Giglio E, Copparoni C, Crocetti S, Mandolesi A, Faa G, Coni P, Scartozzi M, Berardi R. Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab. Front Oncol 2021;11:736104. [PMID: 34660299 DOI: 10.3389/fonc.2021.736104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 43 |
Singh T, Fatehi Hassanabad M, Fatehi Hassanabad A. Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. Biochim Biophys Acta Rev Cancer 2021;1876:188636. [PMID: 34655692 DOI: 10.1016/j.bbcan.2021.188636] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 44 |
Kumar SU, Priya Doss CG. Computational investigation to identify potent inhibitors of the GTPase-Kirsten RAt sarcoma virus (K-Ras) mutants G12C and G12D. Comput Biol Med 2021;139:104946. [PMID: 34715554 DOI: 10.1016/j.compbiomed.2021.104946] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 45 |
Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J Gastroenterol 2021;27:5851-89. [PMID: 34629806 DOI: 10.3748/wjg.v27.i35.5851] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 46 |
Sreedurgalakshmi K, Srikar R, Harikrishnan K, Srinivasan L, Rajkumari R. Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib. Technol Cancer Res Treat 2021;20:15330338211041453. [PMID: 34542333 DOI: 10.1177/15330338211041453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 47 |
Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okołów M, Dzięgiel P. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers (Basel) 2021;13:4705. [PMID: 34572931 DOI: 10.3390/cancers13184705] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 48 |
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM. Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges. Lung Cancer 2021;162:42-53. [PMID: 34739853 DOI: 10.1016/j.lungcan.2021.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 49 |
Orlov-Slavu MC, Popa AM, Tulin A, Pantea Stoian A, Poiana C, Paleru C, Calu V, Nitipir C. The Utility of Next-Generation Sequencing in the Treatment Decision-Making for Metastatic Non-Small-Cell Lung Cancer. Cureus 2021;13:e16919. [PMID: 34513491 DOI: 10.7759/cureus.16919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 50 |
Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev 2021;40:819-35. [PMID: 34499267 DOI: 10.1007/s10555-021-09990-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 51 |
Li H, Qi W, Wang Y, Meng L. Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead. Genes & Diseases 2021. [DOI: 10.1016/j.gendis.2021.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 52 |
Nikitidis G, Carlsson AC, Karlsson S, Campbell AD, Cook C, Dai K, Emtenäs H, Jonson AC, Leek H, Malmgren M, Moravčík Š, Pithani S, Tatton MR, Zhao H, Öhlén K. Synthetic and Chromatographic Challenges and Strategies for Multigram Manufacture of KRAS G12C Inhibitors. Org Process Res Dev . [DOI: 10.1021/acs.oprd.1c00179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 53 |
Lindsay CR, Garassino MC, Nadal E, Öhrling K, Scheffler M, Mazières J. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. Lung Cancer 2021;160:152-65. [PMID: 34417059 DOI: 10.1016/j.lungcan.2021.07.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 54 |
Hamilton G, Plangger A. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics. Expert Opin Drug Metab Toxicol 2021;:1-9. [PMID: 34347509 DOI: 10.1080/17425255.2021.1965123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 55 |
Thompson SK, Buckl A, Dossetter AG, Griffen E, Gill A. Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature. Expert Opin Ther Pat 2021;:1-16. [PMID: 34253125 DOI: 10.1080/13543776.2021.1952984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 56 |
Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 57 |
Abdayem P, Planchard D. Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. Eur Respir Rev 2021;30:200294. [PMID: 34289984 DOI: 10.1183/16000617.0294-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 58 |
Nyíri K, Koppány G, Vértessy BG. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift. Cancer Metastasis Rev 2020;39:1091-105. [PMID: 32715349 DOI: 10.1007/s10555-020-09914-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 59 |
Ghimessy A, Radeczky P, Laszlo V, Hegedus B, Renyi-Vamos F, Fillinger J, Klepetko W, Lang C, Dome B, Megyesfalvi Z. Current therapy of KRAS-mutant lung cancer.Cancer Metastasis Rev. 2020;39:1159-1177. [PMID: 32548736 DOI: 10.1007/s10555-020-09903-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 60 |
Hofman P. What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy. JMP 2021;2:147-72. [DOI: 10.3390/jmp2020015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 61 |
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2021;6:201. [PMID: 34054126 DOI: 10.1038/s41392-021-00572-w] [Cited by in Crossref: 260] [Cited by in F6Publishing: 249] [Article Influence: 130.0] [Reference Citation Analysis]
|
| 62 |
Hopstaken JS, de Ruiter JC, Damhuis RAM, de Langen AJ, van Diessen JNA, Klomp HM, Klompenhouwer EG, Hartemink KJ. Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives. Cancer Treat Res Commun 2021;28:100404. [PMID: 34058517 DOI: 10.1016/j.ctarc.2021.100404] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 63 |
Yu J, Du Y, Mekhail T, Socinski MA, Chang CC. Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy. Clin Lung Cancer 2021:S1525-7304(21)00097-8. [PMID: 34119437 DOI: 10.1016/j.cllc.2021.04.010] [Reference Citation Analysis]
|
| 64 |
Xie M, Xu X, Fan Y. KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup. Front Oncol 2021;11:672612. [PMID: 34012925 DOI: 10.3389/fonc.2021.672612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 65 |
Battaglin F, Randon G, Raimondi A, Pagani F, Arai H, Pietrantonio F, Lenz H. Molecular Determinants of Gastrointestinal Cancers. Advances in Oncology 2021;1:311-325. [DOI: 10.1016/j.yao.2021.02.026] [Reference Citation Analysis]
|
| 66 |
Yang A, Li M, Fang M. The Research Progress of Direct KRAS G12C Mutation Inhibitors. Pathol Oncol Res 2021;27:631095. [PMID: 34257597 DOI: 10.3389/pore.2021.631095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 67 |
Özdoğan M, Papadopoulou E, Tsoulos N, Tsantikidi A, Mariatou VM, Tsaousis G, Kapeni E, Bourkoula E, Fotiou D, Kapetsis G, Boukovinas I, Touroutoglou N, Fassas A, Adamidis A, Kosmidis P, Trafalis D, Galani E, Lypas G, Orhan B, Tansan S, Özatlı T, Kırca O, Çakır O, Nasioulas G. Comprehensive tumor molecular profile analysis in clinical practice. BMC Med Genomics 2021;14:105. [PMID: 33853586 DOI: 10.1186/s12920-021-00952-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 68 |
Catalano A, Adlesic M, Kaltenbacher T, Klar RFU, Albers J, Seidel P, Brandt LP, Hejhal T, Busenhart P, Röhner N, Zodel K, Fritsch K, Wild PJ, Duyster J, Fritsch R, Brummer T, Frew IJ. Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Cancers (Basel) 2021;13:1852. [PMID: 33924486 DOI: 10.3390/cancers13081852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 69 |
Noordhof AL, Damhuis RAM, Hendriks LEL, de Langen AJ, Timens W, Venmans BJW, van Geffen WH. Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. Lung Cancer 2021;155:163-9. [PMID: 33838467 DOI: 10.1016/j.lungcan.2021.04.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 70 |
Koch PD, Quintana J, Ahmed M, Kohler RH, Weissleder R. SMALL MOLECULE IMAGING AGENT FOR MUTANT KRAS G12C. Adv Ther (Weinh) 2021;4:2000290. [PMID: 33997272 DOI: 10.1002/adtp.202000290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 71 |
Gregory TA, Chumbley LB, Henson JW, Theeler BJ. Adult pilocytic astrocytoma in the molecular era: a comprehensive review. CNS Oncol 2021;10:CNS68. [PMID: 33448230 DOI: 10.2217/cns-2020-0027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 72 |
Volckmar AL, Christopoulos P, Kirchner M, Allgäuer M, Neumann O, Budczies J, Rempel E, Horak P, Glade J, Goldschmid H, Seker-Cin H, Brandt R, Kriegsmann M, Leichsenring J, Winter H, Faehling M, Fischer JR, Heußel CP, Herth F, Brummer T, Fröhling S, Schirmacher P, Thomas M, Endris V, Penzel R, Kazdal D, Bochtler T, Stenzinger A. Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field. Lung Cancer 2021;154:131-41. [PMID: 33667718 DOI: 10.1016/j.lungcan.2021.02.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 73 |
Noë M, Hong SM, Wood LD, Thompson ED, Roberts NJ, Goggins MG, Klein AP, Eshleman JR, Kern SE, Hruban RH. Pancreatic cancer pathology viewed in the light of evolution. Cancer Metastasis Rev 2021. [PMID: 33555482 DOI: 10.1007/s10555-020-09953-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 74 |
Gabizon R, London N. The rise of covalent proteolysis targeting chimeras. Curr Opin Chem Biol 2021;62:24-33. [PMID: 33549806 DOI: 10.1016/j.cbpa.2020.12.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 75 |
Danesi R, Fogli S, Indraccolo S, Del Re M, Dei Tos AP, Leoncini L, Antonuzzo L, Bonanno L, Guarneri V, Pierini A, Amunni G, Conte P. Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. ESMO Open 2021;6:100040. [PMID: 33540286 DOI: 10.1016/j.esmoop.2020.100040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 76 |
Pikman Y, Stieglitz E. Targeting the Ras pathway in pediatric hematologic malignancies. Curr Opin Pediatr 2021;33:49-58. [PMID: 33394740 DOI: 10.1097/MOP.0000000000000981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 77 |
Jo J. New Molecular Targeted Therapy of Metastatic Colorectal Cancer. Ewha Med J 2021;44:11-18. [DOI: 10.12771/emj.2021.44.1.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 78 |
Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med 2021;2:100186. [PMID: 33521700 DOI: 10.1016/j.xcrm.2020.100186] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 79 |
Nussinov R, Jang H, Gursoy A, Keskin O, Gaponenko V. Inhibition of Nonfunctional Ras. Cell Chem Biol 2021;28:121-33. [PMID: 33440168 DOI: 10.1016/j.chembiol.2020.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 80 |
Buqué A, Galluzzi L. Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons. Methods Cell Biol 2021;163:xvii-xxv. [PMID: 33785172 DOI: 10.1016/S0091-679X(21)00040-6] [Reference Citation Analysis]
|
| 81 |
De Vita E. 10 years into the resurgence of covalent drugs. Future Med Chem 2021;13:193-210. [PMID: 33275063 DOI: 10.4155/fmc-2020-0236] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 82 |
Thompson ED, Roberts NJ, Wood LD, Eshleman JR, Goggins MG, Kern SE, Klein AP, Hruban RH. The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Mod Pathol 2020;33:2544-63. [PMID: 32704031 DOI: 10.1038/s41379-020-0629-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 83 |
Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. JAMA Oncol 2020;6:1931-8. [PMID: 33057591 DOI: 10.1001/jamaoncol.2020.4643] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 84 |
Chen H, Smaill JB, Liu T, Ding K, Lu X. Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. J Med Chem 2020;63:14404-24. [PMID: 33225706 DOI: 10.1021/acs.jmedchem.0c01312] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 85 |
Korzeniecki C, Priefer R. Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway. Eur J Med Chem 2021;211:113006. [PMID: 33228976 DOI: 10.1016/j.ejmech.2020.113006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 86 |
Baillie TA. Approaches to mitigate the risk of serious adverse reactions in covalent drug design. Expert Opin Drug Discov 2021;16:275-87. [PMID: 33006907 DOI: 10.1080/17460441.2021.1832079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 87 |
Baltanás FC, Zarich N, Rojas-Cabañeros JM, Santos E. SOS GEFs in health and disease. Biochim Biophys Acta Rev Cancer 2020;1874:188445. [PMID: 33035641 DOI: 10.1016/j.bbcan.2020.188445] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 88 |
Brcic L, Kern I. Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists. Transl Lung Cancer Res 2020;9:2194-8. [PMID: 33209643 DOI: 10.21037/tlcr-20-297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 89 |
Upadhya A, Yadav KS, Misra A. Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. Expert Opin Drug Deliv 2021;18:73-102. [PMID: 32954834 DOI: 10.1080/17425247.2021.1825377] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 90 |
Xiang L, Fu X, Wang X, Li W, Zheng X, Nan K, Tian T. A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma. Front Oncol 2020;10:559896. [PMID: 33072585 DOI: 10.3389/fonc.2020.559896] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 91 |
Sayyed-Ahmad A, Gorfe AA. How to make an undruggable enzyme druggable: lessons from ras proteins. Adv Protein Chem Struct Biol 2020;122:181-202. [PMID: 32951811 DOI: 10.1016/bs.apcsb.2020.05.003] [Reference Citation Analysis]
|
| 92 |
Suster DI, Mino-Kenudson M. Molecular Pathology of Primary Non-small Cell Lung Cancer. Arch Med Res 2020;51:784-98. [PMID: 32873398 DOI: 10.1016/j.arcmed.2020.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 93 |
De Vita E, Maneiro M, Tate EW. The Missing Link between (Un)druggable and Degradable KRAS. ACS Cent Sci 2020;6:1281-4. [PMID: 32875070 DOI: 10.1021/acscentsci.0c00920] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 94 |
Cohen R, Pudlarz T, Delattre JF, Colle R, André T. Molecular Targets for the Treatment of Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E2350. [PMID: 32825275 DOI: 10.3390/cancers12092350] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 95 |
Gong H, Nie D, Li Z. Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy. Curr Cancer Drug Targets 2020;20:853-67. [PMID: 32807056 DOI: 10.2174/1568009620999200816130218] [Reference Citation Analysis]
|
| 96 |
Marshall CB, Kleinjan F, Gebregiworgis T, Lee K, Fang Z, Eves BJ, Liu NF, Gasmi-seabrook GMC, Enomoto M, Ikura M. NMR in integrated biophysical drug discovery for RAS: past, present, and future. J Biomol NMR 2020;74:531-54. [DOI: 10.1007/s10858-020-00338-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 97 |
Ye W, Huang Q, Tang T, Qin G. Synergistic effects of piperlongumine and gemcitabine against KRAS mutant lung cancer. Tumori 2021;107:119-24. [PMID: 32515291 DOI: 10.1177/0300891620930789] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 98 |
Jin C, Yang B. Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report. Case Rep Oncol 2020;13:601-5. [PMID: 32595469 DOI: 10.1159/000507568] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 99 |
John S. Current perspective on the treatment of advanced/metastatic colorectal cancer. Onkologie 2020;14:126-130. [DOI: 10.36290/xon.2020.025] [Reference Citation Analysis]
|
| 100 |
Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS. Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. Am Soc Clin Oncol Educ Book 2020;40:e292-308. [PMID: 32453634 DOI: 10.1200/EDBK_280845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 101 |
Smeltzer MP, Wynes MW, Lantuejoul S, Soo R, Ramalingam SS, Varella-Garcia M, Meadows Taylor M, Richeimer K, Wood K, Howell KE, Dalurzo ML, Felip E, Hollenbeck G, Kerr K, Kim ES, Mathias C, Pacheco J, Postmus P, Powell C, Tsuboi M, Wistuba II, Wakelee HA, Belani CP, Scagliotti GV, Hirsch FR. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol 2020;15:1434-48. [PMID: 32445813 DOI: 10.1016/j.jtho.2020.05.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 20.3] [Reference Citation Analysis]
|
| 102 |
Schirripa M, Nappo F, Cremolini C, Salvatore L, Rossini D, Bensi M, Businello G, Pietrantonio F, Randon G, Fucà G, Boccaccino A, Bergamo F, Lonardi S, Dei Tos AP, Fassan M, Loupakis F. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Clin Colorectal Cancer 2020;19:219-25. [PMID: 32605718 DOI: 10.1016/j.clcc.2020.04.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 103 |
Santos RM, Moreno C, Zhang WC. Non-Coding RNAs in Lung Tumor Initiation and Progression. Int J Mol Sci 2020;21:E2774. [PMID: 32316322 DOI: 10.3390/ijms21082774] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
